Last reviewed · How we verify
Prevention of CMV Disease After Kidney-Pancreas Transplantation
Approved treatments
- Valcyte · Cheplapharm
Valcyte works by inhibiting the replication of cytomegalovirus DNA through its action as a nucleoside analog DNA polymerase inhibitor. - Cytovene · Roche Palo
GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of CMV Disease After Kidney-Pancreas Transplantation patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of CMV Disease After Kidney-Pancreas Transplantation treatment landscape brief
- Prevention of CMV Disease After Kidney-Pancreas Transplantation treatment updates RSS
Frequently asked questions about Prevention of CMV Disease After Kidney-Pancreas Transplantation
What drugs treat Prevention of CMV Disease After Kidney-Pancreas Transplantation?
Tracked treatments include Valcyte, Cytovene.
What is the treatment for Prevention of CMV Disease After Kidney-Pancreas Transplantation?
Standard treatment for Prevention of CMV Disease After Kidney-Pancreas Transplantation includes Valcyte, Cytovene. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of CMV Disease After Kidney-Pancreas Transplantation patent cliff · Prevention of CMV Disease After Kidney-Pancreas Transplantation CI report
- Treatment: Valcyte · Cheplapharm
- Treatment: Cytovene · Roche Palo
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing